Mumbai, Sept. 4 -- Cipla said that its wholly owned subsidiary Invagen Pharmaceuticals has entered into a strategic partnership with Qilu Pharmaceutical Co. for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for United States.

Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs).

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the de...